High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: The results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial

Norio Shiba, Kentaro Ohki, Tohru Kobayashi, Yusuke Hara, Genki Yamato, Reo Tanoshima, Hitoshi Ichikawa, Daisuke Tomizawa, Myoung Ja Park, Akira Shimada, Manabu Sotomatsu, Hirokazu Arakawa, Keizo Horibe, Souichi Adachi, Takashi Taga, Akio Tawa, Yasuhide Hayashi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recent reports described the NUP98-NSD1 fusion as an adverse prognostic marker for acute myeloid leukaemia (AML) and PRDM16 (also known as MEL1) as the representative overexpressed gene in patients harbouring NUP98-NSD1 fusion. PRDM16 gene expression levels were measured via real-time polymerase chain reaction in 369 paediatric patients with de novo AML, of whom 84 (23%) exhibited PRDM16 overexpression (PRDM16/ABL1 ratio ≥0·010). The frequencies of patients with high or low PRDM16 expression differed widely with respect to each genetic alteration, as follows: t(8;21), 4% vs. 96%, P <0·001; inv(16), 0% vs. 100%, P <0·001; KMT2A (also termed MLL)- partial tandem duplication, 100% vs. 0%, P <0·001; NUP98-NSD1, 100% vs. 0%, P <0·001. The overall survival (OS) and event-free survival (EFS) among PRDM16-overexpressing patients were significantly worse than in patients with low PRDM16 expression (3-year OS: 51% vs. 81%, P <0·001, 3-year EFS: 32% vs. 64%, P <0·001) irrespective of other cytogenetic alterations except for NPM1. PRDM16 gene expression was particularly useful for stratifying FLT3-internal tandem duplication-positive AML patients (3-year OS: high = 30% vs. low = 70%, P <0·001). PRDM16 overexpression was highly recurrent in de novo paediatric AML patients with high/intermediate-risk cytogenetic profiles and was independently associated with an adverse outcome.

Original languageEnglish
Pages (from-to)581-591
Number of pages11
JournalBritish Journal of Haematology
Volume172
Issue number4
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Acute Myeloid Leukemia
Lymphoma
Leukemia
Pediatrics
Cytogenetics
Disease-Free Survival
Survival
Gene Expression
nuclear pore complex protein 98
Real-Time Polymerase Chain Reaction
Genes

Keywords

  • AML
  • NUP98-NSD1
  • FLT3-ITD
  • Gene expression
  • KMT2A-PTD
  • PRDM16

ASJC Scopus subject areas

  • Hematology

Cite this

High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1 : The results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial. / Shiba, Norio; Ohki, Kentaro; Kobayashi, Tohru; Hara, Yusuke; Yamato, Genki; Tanoshima, Reo; Ichikawa, Hitoshi; Tomizawa, Daisuke; Park, Myoung Ja; Shimada, Akira; Sotomatsu, Manabu; Arakawa, Hirokazu; Horibe, Keizo; Adachi, Souichi; Taga, Takashi; Tawa, Akio; Hayashi, Yasuhide.

In: British Journal of Haematology, Vol. 172, No. 4, 01.02.2016, p. 581-591.

Research output: Contribution to journalArticle

Shiba, N, Ohki, K, Kobayashi, T, Hara, Y, Yamato, G, Tanoshima, R, Ichikawa, H, Tomizawa, D, Park, MJ, Shimada, A, Sotomatsu, M, Arakawa, H, Horibe, K, Adachi, S, Taga, T, Tawa, A & Hayashi, Y 2016, 'High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: The results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial', British Journal of Haematology, vol. 172, no. 4, pp. 581-591. https://doi.org/10.1111/bjh.13869
Shiba, Norio ; Ohki, Kentaro ; Kobayashi, Tohru ; Hara, Yusuke ; Yamato, Genki ; Tanoshima, Reo ; Ichikawa, Hitoshi ; Tomizawa, Daisuke ; Park, Myoung Ja ; Shimada, Akira ; Sotomatsu, Manabu ; Arakawa, Hirokazu ; Horibe, Keizo ; Adachi, Souichi ; Taga, Takashi ; Tawa, Akio ; Hayashi, Yasuhide. / High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1 : The results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial. In: British Journal of Haematology. 2016 ; Vol. 172, No. 4. pp. 581-591.
@article{0e33ffdf6cfd4e0582223cbe358d4b30,
title = "High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: The results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial",
abstract = "Recent reports described the NUP98-NSD1 fusion as an adverse prognostic marker for acute myeloid leukaemia (AML) and PRDM16 (also known as MEL1) as the representative overexpressed gene in patients harbouring NUP98-NSD1 fusion. PRDM16 gene expression levels were measured via real-time polymerase chain reaction in 369 paediatric patients with de novo AML, of whom 84 (23{\%}) exhibited PRDM16 overexpression (PRDM16/ABL1 ratio ≥0·010). The frequencies of patients with high or low PRDM16 expression differed widely with respect to each genetic alteration, as follows: t(8;21), 4{\%} vs. 96{\%}, P <0·001; inv(16), 0{\%} vs. 100{\%}, P <0·001; KMT2A (also termed MLL)- partial tandem duplication, 100{\%} vs. 0{\%}, P <0·001; NUP98-NSD1, 100{\%} vs. 0{\%}, P <0·001. The overall survival (OS) and event-free survival (EFS) among PRDM16-overexpressing patients were significantly worse than in patients with low PRDM16 expression (3-year OS: 51{\%} vs. 81{\%}, P <0·001, 3-year EFS: 32{\%} vs. 64{\%}, P <0·001) irrespective of other cytogenetic alterations except for NPM1. PRDM16 gene expression was particularly useful for stratifying FLT3-internal tandem duplication-positive AML patients (3-year OS: high = 30{\%} vs. low = 70{\%}, P <0·001). PRDM16 overexpression was highly recurrent in de novo paediatric AML patients with high/intermediate-risk cytogenetic profiles and was independently associated with an adverse outcome.",
keywords = "AML, NUP98-NSD1, FLT3-ITD, Gene expression, KMT2A-PTD, PRDM16",
author = "Norio Shiba and Kentaro Ohki and Tohru Kobayashi and Yusuke Hara and Genki Yamato and Reo Tanoshima and Hitoshi Ichikawa and Daisuke Tomizawa and Park, {Myoung Ja} and Akira Shimada and Manabu Sotomatsu and Hirokazu Arakawa and Keizo Horibe and Souichi Adachi and Takashi Taga and Akio Tawa and Yasuhide Hayashi",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/bjh.13869",
language = "English",
volume = "172",
pages = "581--591",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1

T2 - The results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial

AU - Shiba, Norio

AU - Ohki, Kentaro

AU - Kobayashi, Tohru

AU - Hara, Yusuke

AU - Yamato, Genki

AU - Tanoshima, Reo

AU - Ichikawa, Hitoshi

AU - Tomizawa, Daisuke

AU - Park, Myoung Ja

AU - Shimada, Akira

AU - Sotomatsu, Manabu

AU - Arakawa, Hirokazu

AU - Horibe, Keizo

AU - Adachi, Souichi

AU - Taga, Takashi

AU - Tawa, Akio

AU - Hayashi, Yasuhide

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Recent reports described the NUP98-NSD1 fusion as an adverse prognostic marker for acute myeloid leukaemia (AML) and PRDM16 (also known as MEL1) as the representative overexpressed gene in patients harbouring NUP98-NSD1 fusion. PRDM16 gene expression levels were measured via real-time polymerase chain reaction in 369 paediatric patients with de novo AML, of whom 84 (23%) exhibited PRDM16 overexpression (PRDM16/ABL1 ratio ≥0·010). The frequencies of patients with high or low PRDM16 expression differed widely with respect to each genetic alteration, as follows: t(8;21), 4% vs. 96%, P <0·001; inv(16), 0% vs. 100%, P <0·001; KMT2A (also termed MLL)- partial tandem duplication, 100% vs. 0%, P <0·001; NUP98-NSD1, 100% vs. 0%, P <0·001. The overall survival (OS) and event-free survival (EFS) among PRDM16-overexpressing patients were significantly worse than in patients with low PRDM16 expression (3-year OS: 51% vs. 81%, P <0·001, 3-year EFS: 32% vs. 64%, P <0·001) irrespective of other cytogenetic alterations except for NPM1. PRDM16 gene expression was particularly useful for stratifying FLT3-internal tandem duplication-positive AML patients (3-year OS: high = 30% vs. low = 70%, P <0·001). PRDM16 overexpression was highly recurrent in de novo paediatric AML patients with high/intermediate-risk cytogenetic profiles and was independently associated with an adverse outcome.

AB - Recent reports described the NUP98-NSD1 fusion as an adverse prognostic marker for acute myeloid leukaemia (AML) and PRDM16 (also known as MEL1) as the representative overexpressed gene in patients harbouring NUP98-NSD1 fusion. PRDM16 gene expression levels were measured via real-time polymerase chain reaction in 369 paediatric patients with de novo AML, of whom 84 (23%) exhibited PRDM16 overexpression (PRDM16/ABL1 ratio ≥0·010). The frequencies of patients with high or low PRDM16 expression differed widely with respect to each genetic alteration, as follows: t(8;21), 4% vs. 96%, P <0·001; inv(16), 0% vs. 100%, P <0·001; KMT2A (also termed MLL)- partial tandem duplication, 100% vs. 0%, P <0·001; NUP98-NSD1, 100% vs. 0%, P <0·001. The overall survival (OS) and event-free survival (EFS) among PRDM16-overexpressing patients were significantly worse than in patients with low PRDM16 expression (3-year OS: 51% vs. 81%, P <0·001, 3-year EFS: 32% vs. 64%, P <0·001) irrespective of other cytogenetic alterations except for NPM1. PRDM16 gene expression was particularly useful for stratifying FLT3-internal tandem duplication-positive AML patients (3-year OS: high = 30% vs. low = 70%, P <0·001). PRDM16 overexpression was highly recurrent in de novo paediatric AML patients with high/intermediate-risk cytogenetic profiles and was independently associated with an adverse outcome.

KW - AML

KW - NUP98-NSD1

KW - FLT3-ITD

KW - Gene expression

KW - KMT2A-PTD

KW - PRDM16

UR - http://www.scopus.com/inward/record.url?scp=84956912084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956912084&partnerID=8YFLogxK

U2 - 10.1111/bjh.13869

DO - 10.1111/bjh.13869

M3 - Article

C2 - 26684393

AN - SCOPUS:84956912084

VL - 172

SP - 581

EP - 591

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -